OXSR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ruxolitinib (SCHEMBL99225)	1.00	1/20
Ruxolitinib (SCHEMBL101279)	1.00	1/20
Plx-4720 (SCHEMBL133733)	1.00	1/20
Ruxolitinib (SCHEMBL171319)	1.00	1/20
SCHEMBL99245	0.98	1/20
SCHEMBL99371	0.98	1/20
SCHEMBL103135	0.98	1/20
SCHEMBL298760	0.90	1/20
SCHEMBL298198	0.88	1/20
SCHEMBL298282	0.84	1/20
Ruxolitinib (SCHEMBL99771)	0.84	1/20
Ruxolitinib (SCHEMBL100078)	0.84	1/20
SCHEMBL298349	0.83	1/20
Vemurafenib (SCHEMBL298931)	0.82	1/20
SCHEMBL101345	0.82	1/20
SCHEMBL294160	0.82	1/20
SCHEMBL297768	0.80	1/20
SCHEMBL298366	0.80	1/20
SCHEMBL298957	0.80	1/20
SCHEMBL298900	0.80	1/20

Clinical trials — most relevant to OXSR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea	PHASE2/PHASE3	COMPLETED
Proteome-based Immunotherapy of Lung Cancer Brain Metastases	PHASE2/PHASE3	UNKNOWN
Proteome-based Personalized Immunotherapy of Glioblastoma	PHASE2/PHASE3	UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study	PHASE1/PHASE2	COMPLETED
Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients	PHASE2	UNKNOWN
Oxytocin for Oxidative Stress and Inflammation	PHASE2	COMPLETED
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes	PHASE2	RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans	PHASE1	COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
Endometriosis and Microvascular Dysfunction: Role of Inflammation	EARLY_PHASE1	RECRUITING
Changes in Glutamatergic Neurotransmission of Severe TBI Patients	EARLY_PHASE1	SUSPENDED
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Genomics of Posttraumatic Stress Disorder in Veterans	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Prospective Genetic Study in Patients With Ovarian Insufficiency	nan	UNKNOWN
TAS1R1, TAS1R3, TLR2, TLR4, CA6 Gene Polymorphism on Dental Caries	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour	nan	UNKNOWN
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a OXSR1 binder may also engage these)

Protein	Name	Similarity
Q863I2	—	0.999	Q863I2 →
Q5R495	—	0.995	Q5R495 →
Q6P9R2	—	0.995	Q6P9R2 →
A0A8I5ZNK2	—	0.992	A0A8I5ZNK2 →
STK39	STE20/SPS1-related proline-alanine-rich protein kinase	0.992	landscape →
O88506	—	0.991	O88506 →
Q9Z1W9	—	0.988	Q9Z1W9 →
PRKD1	Serine/threonine-protein kinase D1	0.973	landscape →
Q62696	—	0.967	Q62696 →
Q62101	—	0.966	Q62101 →
Q9WTQ1	—	0.966	Q9WTQ1 →
A0A8C0TYJ0	—	0.965	A0A8C0TYJ0 →
Q08CW1	—	0.965	Q08CW1 →
Q1ECX4	—	0.964	Q1ECX4 →
P43249	—	0.964	P43249 →
Q8VEB1	—	0.961	Q8VEB1 →
O55047	—	0.960	O55047 →
Q5XIS9	—	0.960	Q5XIS9 →
Q811D0	—	0.959	Q811D0 →
Q28C55	—	0.959	Q28C55 →
Q12959	—	0.959	Q12959 →
Q8CFE4	—	0.958	Q8CFE4 →
Q8BZ03	—	0.958	Q8BZ03 →
Q5PYH5	—	0.958	Q5PYH5 →
D2XV59	—	0.957	D2XV59 →
Q62833	—	0.957	Q62833 →
MAPKAPK2	MAP kinase-activated protein kinase 2	0.957	landscape →
P00535	—	0.957	P00535 →
GRK5	G protein-coupled receptor kinase 5	0.957	landscape →
Q6ZI44	—	0.957	Q6ZI44 →